Distinct molecular mechanisms underlying clinically re gene expression analyses across three different platforr

Citation Report

#	Article	IF	Citations
1	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. Breast Cancer Research, 2006, 8, 214.	2.2	28
2	Gene Expression Profiling and Clinical Outcome in Breast Cancer. OMICS A Journal of Integrative Biology, 2006, 10, 429-443.	1.0	60
3	Data Perturbation Independent Diagnosis and Validation of Breast Cancer Subtypes Using Clustering and Patterns. Cancer Informatics, 2006, 2, 117693510600200.	0.9	10
5	Expression profiling of lipopolysaccharide target genes in RAW264.7 cells by oligonucleotide microarray analyses. Archives of Pharmacal Research, 2006, 29, 890-897.	2.7	17
6	Clinicians' guide to microarrays. Surgical Oncology, 2006, 15, 205-210.	0.8	5
7	Comparison of Age Distribution Patterns for Different Histopathologic Types of Breast Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1899-1905.	1.1	130
8	Demystifying basal-like breast carcinomas. Journal of Clinical Pathology, 2006, 60, 1328-1332.	1.0	51
9	Breast Cancer Heterogeneity: A Mixture of At Least Two Main Types?. Journal of the National Cancer Institute, 2006, 98, 948-951.	3.0	104
10	Framework for Identifying Common Aberrations in DNA Copy Number Data. , 2007, , 122-136.		8
11	Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Review of Anticancer Therapy, 2007, 7, 1243-1253.	1.1	8
12	Challenges in Projecting Clustering Results Across Gene Expression–Profiling Datasets. Journal of the National Cancer Institute, 2007, 99, 1715-1723.	3.0	88
13	The Phenotypic Spectrum of Basal-like Breast Cancers: A Critical Appraisal. Advances in Anatomic Pathology, 2007, 14, 358-373.	2.4	70
14	Comparing Genetically Engineered Mouse Mammary Cancer Models with Human Breast Cancer by Expression Profiling1. Breast Disease, 2007, 28, 39-51.	0.4	13
15	Gene expression profiling in breast cancer. Current Opinion in Oncology, 2007, 19, 547-551.	1.1	46
16	Transcriptomic signatures in breast cancer. Molecular BioSystems, 2007, 3, 466.	2.9	10
17	High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates. Cancer Research, 2007, 67, 10669-10676.	0.4	190
18	Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Molecular Oncology, 2007, 1, 160-171.	2.1	128
19	Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: Relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Molecular Oncology, 2007, 1, 321-349.	2.1	24

#	ARTICLE	IF	CITATIONS
20	Origins of breast cancer subtypes and therapeutic implications. Nature Clinical Practice Oncology, 2007, 4, 516-525.	4.3	155
22	Genomic signatures of breast cancer metastasis. Cytogenetic and Genome Research, 2007, 118, 116-129.	0.6	8
23	Gene Expression Signature in Peripheral Blood Detects Thoracic Aortic Aneurysm. PLoS ONE, 2007, 2, e1050.	1.1	85
24	Breast cancer: origins and evolution. Journal of Clinical Investigation, 2007, 117, 3155-3163.	3.9	488
25	Breast Cancer among Hispanic and non-Hispanic White Women in Arizona. Journal of Health Care for the Poor and Underserved, 2007, 18, 130-145.	0.4	26
26	Tissue microarrays for testing basal biomarkers in familial breast cancer cases. Sao Paulo Medical Journal, 2007, 125, 226-230.	0.4	3
27	Comparison of gene expression data from human and mouse breast cancers: Identification of a conserved breast tumor gene set. International Journal of Cancer, 2007, 121, 683-688.	2.3	30
28	Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 2007, 110, 1687-1696.	2.0	88
29	Racial disparities in breast cancer outcome. Cancer, 2007, 110, 1880-1888.	2.0	45
30	Portraits of breast cancer progression. BMC Bioinformatics, 2007, 8, 291.	1.2	32
31	Using specific cytotoxics with a targeted mind. Breast, 2007, 16, 120-126.	0.9	35
32	Re: A Molecular Correlate to the Gleason Grading System for Prostate Adenocarcinoma. European Urology, 2007, 51, 851-852.	0.9	0
33	Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. Journal of Cellular and Molecular Medicine, 2007, 11, 981-1011.	1.6	213
34	Genetic studies of diseases. Cellular and Molecular Life Sciences, 2007, 64, 1752-1762.	2.4	113
35	Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer. Cellular and Molecular Life Sciences, 2007, 64, 3185-3200.	2.4	11
36	Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer. Cellular and Molecular Life Sciences, 2007, 64, 3219-3232.	2.4	22
37	Molecular profiling in breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 185-198.	2.6	35
38	Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Research and Treatment, 2007, 106, 439-451.	1.1	94

#	Article	IF	Citations
39	Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment, 2008, 109, 123-139.	1.1	747
40	Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer, 2008, 15, 153-158.	1.3	32
41	Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Medical Genomics, 2008, 1, 11.	0.7	67
42	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets â€" improving meta-analysis and prediction of prognosis. BMC Medical Genomics, 2008, 1, 42.	0.7	134
43	High prevalence of tripleâ€negative tumors in an urban cancer center. Cancer, 2008, 113, 608-615.	2.0	70
44	How basal are tripleâ€negative breast cancers?. International Journal of Cancer, 2008, 123, 236-240.	2.3	384
45	Analysis of Gene Expression Identifies Differentially Expressed Genes and Pathways Associated with Lymphatic Dissemination in Patients with Adenocarcinoma of the Esophagus. Annals of Surgical Oncology, 2008, 15, 3459-3470.	0.7	29
47	CD109 expression in basalâ€like breast carcinoma. Pathology International, 2008, 58, 288-294.	0.6	49
48	High throughput molecular diagnostics in bladder cancer â€" on the brink of clinical utility. Molecular Oncology, 2008, 1, 384-394.	2.1	20
49	Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors. BMC Genomics, 2008, 9, 379.	1.2	53
50	Characterization of breast cancer subtypes by quantitative assessment of biological parameters: Relationship with clinicopathological characteristics, biological features and prognosis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 141, 147-152.	0.5	13
51	Basal-Like Breast Cancer: A Critical Review. Journal of Clinical Oncology, 2008, 26, 2568-2581.	0.8	784
52	Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype. Clinical Cancer Research, 2008, 14, 1368-1376.	3.2	1,040
53	Gene Expression Profiling of Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 67-97.	9.6	66
54	Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial. Future Oncology, 2008, 4, 603-610.	1.1	107
56	Functional genomics in translational cancer research: focus on breast cancer. Briefings in Functional Genomics & Proteomics, 2008, 7, 1-7.	3.8	3
57	p53â€repressed miRNAs are involved with E2F in a feedâ€forward loop promoting proliferation. Molecular Systems Biology, 2008, 4, 229.	3.2	138
58	Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan disease. Genetics in Medicine, 2008, 10, 675-684.	1.1	20

#	ARTICLE	IF	CITATIONS
59	Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle, 2009, 8, 2031-2040.	1.3	376
60	Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2359-2364.	3.3	101
61	Towards Improved Cancer Diagnosis and Prognosis Using Analysis of Gene Expression Data and Computer Aided Imaging. Experimental Biology and Medicine, 2009, 234, 860-879.	1.1	32
62	Prognostic Applications of Gene Expression Signatures in Breast Cancer. Oncology, 2009, 77, 2-8.	0.9	20
63	Breast Cancer Classification: Time for a Change. Journal of Clinical Oncology, 2009, 27, 2427-2428.	0.8	22
64	Is There a Difference in the Association between Percent Mammographic Density and Subtypes of Breast Cancer? Luminal A and Triple-Negative Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 479-485.	1.1	76
65	Qualitative Age Interactions in Breast Cancer Studies: Mind the Gap. Journal of Clinical Oncology, 2009, 27, 5308-5311.	0.8	38
66	Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us?. Journal of Clinical Pathology, 2009, 62, 879-885.	1.0	31
67	How different are luminal A and basal breast cancers?. International Journal of Cancer, 2009, 124, 1338-1348.	2.3	51
68	Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Research and Treatment, 2009, 115, 349-358.	1.1	18
69	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Research and Treatment, 2009, 113, 357-370.	1.1	332
70	The epidemiology of triple-negative breast cancer, including race. Cancer Causes and Control, 2009, 20, 1071-1082.	0.8	280
71	Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene, 2009, 28, 3926-3936.	2.6	205
72	Unraveling Breast Cancer Heterogeneity Through Transcriptomic and Epigenomic Analysis. Annals of Surgical Oncology, 2009, 16, 2270-2279.	0.7	18
73	Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Human Pathology, 2009, 40, 1224-1233.	1.1	36
74	Molecular profiling and characterization of luminal–like and basal–like <i>in vivo</i> breast cancer xenograft models. Molecular Oncology, 2009, 3, 469-482.	2.1	96
75	Unveiling Fuzzy Associations Between Breast Cancer Prognostic Factors and Gene Expression Data. , 2009, , .		3
76	Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Research, 2009, 11, R69.	2.2	95

#	ARTICLE	IF	CITATIONS
77	Triple negative breast cancers: Clinical and prognostic implications. European Journal of Cancer, 2009, 45, 27-40.	1.3	216
78	Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clinical Cancer Research, 2009, 15, 2302-2310.	3.2	422
79	Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anti-Cancer Drugs, 2009, 20, 946-952.	0.7	6
81	A Review of Triple-Negative Breast Cancer. Cancer Control, 2010, 17, 173-176.	0.7	197
82	High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Research and Treatment, 2010, 122, 661-670.	1.1	127
83	Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment, 2010, 123, 661-677.	1.1	86
84	Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes and Control, 2010, 21, 399-409.	0.8	40
85	Caveolin-1 in Diagnosis and Prognosis of Canine Mammary Tumours: Comparison of Evaluation Systems. Journal of Comparative Pathology, 2010, 143, 87-93.	0.1	9
86	Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer, 2010, 10, 433.	1.1	93
87	Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer, 2010, 10, 502.	1.1	121
88	Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer, 2010, 10, 628.	1.1	101
89	Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer, 2010, 10, 653.	1.1	37
90	Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer, 2010, 10, 656.	1.1	34
91	Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Veterinary Research, 2010, 6, 5.	0.7	84
92	Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: A pathological and immunohistochemical study. Breast, 2010, 19, 137-141.	0.9	21
93	Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes. Cancer, 2010, 116, 2549-2559.	2.0	82
94	Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence. Cancer Science, 2010, 101, 826-830.	1.7	31
95	Distinguishing medullary carcinoma of the breast from high‑grade hormone receptor‑negative invasive ductal carcinoma: an immunohistochemical approach. Histopathology, 2010, 56, 852-859.	1.6	29

#	ARTICLE	IF	CITATIONS
96	Molecular Genetic Markers in Female Reproductive Cancers. Journal of Oncology, 2010, 2010, 1-2.	0.6	1
97	MicroRNAs as Novel Biomarkers for Breast Cancer. Journal of Oncology, 2010, 2010, 1-7.	0.6	121
98	Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients. Clinics, 2010, 65, 1033-1036.	0.6	43
99	Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer. Journal of Clinical Oncology, 2010, 28, 232-239.	0.8	355
100	Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer. Clinical Cancer Research, 2010, 16, 876-887.	3.2	364
101	Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study. Cancer Research, 2010, 70, 575-587.	0.4	100
102	What Can We Learn about Disease Etiology from Case-Case Analyses? Lessons from Breast Cancer: Figure 1.. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2710-2714.	1.1	42
103	Neighborhood Rough Set Reduction-Based Gene Selection and Prioritization for Gene Expression Profile Analysis and Molecular Cancer Classification. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-12.	3.0	9
104	Differential Protein Expression Profiles in Estrogen Receptor-Positive and -Negative Breast Cancer Tissues Using Label-Free Quantitative Proteomics. Genes and Cancer, 2010, 1, 251-271.	0.6	38
105	Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy. Laboratory Medicine, 2010, 41, 364-372.	0.8	30
107	Molecular basis for therapy resistance. Molecular Oncology, 2010, 4, 284-300.	2.1	37
108	Breast Cancer Biology and Clinical Characteristics. , 2010, , 21-46.		11
109	Triple-negative breast cancer: a clinical update. Community Oncology, 2010, 7, 203-211.	0.2	32
110	Quality Assessment of Transcriptome Data Using Intrinsic Statistical Properties. Genomics, Proteomics and Bioinformatics, 2010, 8, 57-71.	3.0	15
111	Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Molecular Oncology, 2011, 5, 61-76.	2.1	110
112	Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Annals of Oncology, 2011, 22, 1288-1294.	0.6	103
113	Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer. BMC Research Notes, 2011, 4, 397.	0.6	7
114	Differential expression of genes in retinoblastoma. Clinica Chimica Acta, 2011, 412, 2015-2021.	0.5	9

#	ARTICLE	IF	CITATIONS
115	Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells. Cell, 2011, 146, 633-644.	13.5	1,334
116	Cancer microRNAs: From subtype profiling to predictors of response to therapy. Trends in Molecular Medicine, 2011, 17, 235-243.	3.5	68
117	Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends in Pharmacological Sciences, 2011, 32, 644-651.	4.0	60
118	Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 470-477.	3.0	190
119	Circulating Tumour Cells: Implications and Methods of Detection. , 0, , .		2
120	Translational Research on Breast Cancer: miRNA, siRNA and Immunoconjugates in Conjugation with Nanotechnology for Clinical Studies. , 0, , .		0
121	Metformin: Its emerging role in oncology. Hormones, 2011, 10, 5-15.	0.9	40
122	Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care, 2011, 6, 265-272.	0.8	12
123	miRNA Biomarkers in Breast Cancer Detection and Management. Journal of Cancer, 2011, 2, 116-122.	1.2	103
124	Phenotypic Heterogeneity of Breast Cancer Stem Cells. Journal of Oncology, 2011, 2011, 1-6.	0.6	75
125	Epidemiology of triple negative breast cancers. Breast Disease, 2011, 32, 5-24.	0.4	50
126	â€œTargetingâ€•Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers. Seminars in Oncology, 2011, 38, 254-262.	0.8	19
127	Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition. Cancer Research, 2011, 71, 6621-6632.	0.4	114
128	A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment, 2011, 126, 407-420.	1.1	231
129	Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Research and Treatment, 2011, 128, 301-313.	1.1	57
130	Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Research and Treatment, 2011, 126, 185-192.	1.1	113
131	Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Research and Treatment, 2011, 128, 483-493.	1.1	35
132	Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management. Breast Cancer Research and Treatment, 2011, 130, 421-423.	1.1	1

#	ARTICLE	IF	CITATIONS
133	Risk factors by molecular subtypes of breast cancer across a population-based study of women 56Âyears or younger. Breast Cancer Research and Treatment, 2011, 130, 587-597.	1.1	154
134	Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women. Tumor Biology, 2011, 32, 713-719.	0.8	7
135	Identification of early molecular markers for breast cancer. Molecular Cancer, 2011, 10, 15.	7.9	164
136	Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer, 2011, 10, 86.	7.9	46
137	A Normalized Tree Index for identification of correlated clinical parameters in microarray experiments. BioData Mining, 2011, 4, 2.	2.2	2
138	Bidirectional signaling of mammary epithelium and stroma: implications for breast cancerâ€"preventive actions of dietary factors. Journal of Nutritional Biochemistry, 2011, 22, 605-611.	1.9	18
139	Interactions with Fibroblasts Are Distinct in Basal-Like and Luminal Breast Cancers. Molecular Cancer Research, 2011, 9, 3-13.	1.5	96
140	Genome-wide Gene Expression Profiling of Formalin-fixed Paraffin-Embedded Breast Cancer Core Biopsies Using Microarrays. Journal of Histochemistry and Cytochemistry, 2011, 59, 146-157.	1.3	33
141	Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform. British Journal of Cancer, 2011, 105, 1574-1581.	2.9	15
142	CD44+/CD24â`Cells Are Transit Progenitors and Do Not Determine the Molecular Subtypes and Clinical Parameters in Breast Carcinomas. Ultrastructural Pathology, 2011, 35, 72-78.	0.4	16
143	Basal Phenotype Breast Cancer: Implications for Treatment and Prognosis. Women's Health, 2011, 7, 181-202.	0.7	22
144	Optimally discriminative subnetwork markers predict response to chemotherapy. Bioinformatics, 2011, 27, i205-i213.	1.8	81
145	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Annals of Oncology, 2012, 23, 2578-2584.	0.6	46
146	A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer. International Journal of Molecular Sciences, 2012, 13, 14898-14916.	1.8	19
147	Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts. Molecular Cancer Therapeutics, 2012, 11, 2693-2703.	1.9	39
148	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Annals of Oncology, 2012, 23, 2997-3006.	0.6	233
149	Transcriptomic landscape of breast cancers through mRNA sequencing. Scientific Reports, 2012, 2, 264.	1.6	83
150	Implications of Different CA 15-3 Levels according to Breast Cancer Subtype at Initial Diagnosis of Recurrent or Metastatic Breast Cancer. Oncology, 2012, 82, 180-187.	0.9	10

#	ARTICLE	IF	CITATIONS
151	Basal Breast Cancer: A Complex and Deadly Molecular Subtype. Current Molecular Medicine, 2012, 12, 96-110.	0.6	173
152	Association between body mass index and breast cancer intrinsic subtypes in Japanese women. Experimental and Therapeutic Medicine, 2012, 4, 391-396.	0.8	6
153	Patrón de recidiva en carcinoma mamario. Comparación entre carcinomas hormonodependientes y hormonoindependientes. Revista De Senologia Y Patologia Mamaria, 2012, 25, 8-13.	0.0	0
154	Immunohistochemical profile and clinical-pathological variables in breast cancer. Revista Da Associação Médica Brasileira (English Edition), 2012, 58, 178-187.	0.1	6
156	Molecular subtypes of breast carcinoma in Egyptian women: Clinicopathological features. Pathology Research and Practice, 2012, 208, 382-386.	1.0	25
157	Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Modern Pathology, 2012, 25, 185-196.	2.9	52
158	Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial. BMC Medical Genomics, 2012, 5, 51.	0.7	27
159	Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrow–Derived Cells. Cancer Discovery, 2012, 2, 1150-1165.	7.7	142
160	The Ghrelin Axis—Does It Have an Appetite for Cancer Progression?. Endocrine Reviews, 2012, 33, 849-891.	8.9	75
161	Genome-Wide Expression Profiling of Patients with Primary Open Angle Glaucoma. , 2012, 53, 5899.		12
162	Neoadjuvant Therapy for Triple-Negative Breast Cancer: The Challenge of Translating Biological Concepts into Effective Treatments. Current Breast Cancer Reports, 2012, 4, 240-248.	0.5	0
163	Triple-negative breast cancer: epidemiological considerations and recommendations. Annals of Oncology, 2012, 23, vi7-vi12.	0.6	435
164	Constructing Endophenotypes of Complex Diseases Using Non-Negative Matrix Factorization and Adjusted Rand Index. PLoS ONE, 2012, 7, e40996.	1.1	6
165	A review of the biological and clinical characteristics of luminal–like oestrogen receptor–positive breast cancer. Histopathology, 2012, 60, 854-863.	1.6	22
166	Genomic analysis: Toward a new approach in breast cancer management. Critical Reviews in Oncology/Hematology, 2012, 81, 207-223.	2.0	21
167	Gene expression profiling to dissect the complexity of cancer biology: Pitfalls and promise. Seminars in Cancer Biology, 2012, 22, 250-260.	4.3	28
168	Protein-based identification of quantitative trait loci associated with malignant transformation in two HER2+ cellular models of breast cancer. Proteome Science, 2012, 10, 11.	0.7	7
169	Immunohistochemical study of expression of Caveolin-1 in canine malignant mammary tumour. Comparative Clinical Pathology, 2013, 22, 971-976.	0.3	0

#	ARTICLE	IF	CITATIONS
170	Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. British Journal of Cancer, 2013, 109, 1886-1894.	2.9	40
171	Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. Journal of Proteomics, 2013, 94, 279-288.	1.2	144
172	Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. Biochemical and Biophysical Research Communications, 2013, 434, 695-700.	1.0	75
173	Identification of Triple-negative and Basal-like Canine Mammary Carcinomas using Four Basal Markers. Journal of Comparative Pathology, 2013, 148, 298-306.	0.1	46
174	Hypoxiaâ€inducing factors as master regulators of stemness properties and altered metabolism of cancerâ€and metastasisâ€initiating cells. Journal of Cellular and Molecular Medicine, 2013, 17, 30-54.	1.6	282
175	Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials. Drug Discovery Today, 2013, 18, 128-140.	3.2	26
176	Future clinical applications of genomics for acute respiratory distress syndrome. Lancet Respiratory Medicine,the, 2013, 1, 793-803.	5.2	9
177	â€œThe Infinite Mazeâ€of breast cancer, signaling pathways and radioresistance. Breast, 2013, 22, 411-418.	0.9	13
178	Aberrant promoter hypermethylation of p21 (WAF1/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer. Molecular and Cellular Biochemistry, 2013, 382, 19-26.	1.4	20
179	Expression of SCUBE2 gene declines in high grade endometrial cancer and associates with expression of steroid hormone receptors and tumor suppressor PTEN. Gynecological Endocrinology, 2013, 29, 1031-1035.	0.7	9
180	Fruit and Vegetable Intake and Breast Cancer Risk: A Case for Subtype-Specific Risk?. Journal of the National Cancer Institute, 2013, 105, 164-165.	3.0	12
181	Molecular Classification and Prognostic Signatures of Breast Tumors. , 2013, , 55-62.		0
182	Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biology, 2013, 14, R126.	13.9	80
183	ClasificaciÃ³n en subtipos moleculares de tumores de mama de pequeÃ±os animales mediante mÃ©todos inmunohistoquÃmicos. Sanidad Militar, 2013, 69, 6-12.	0.0	0
184	Differential Peripheral Blood Gene Expression Profile Based on Her2 Expression on Primary Tumors of Breast Cancer Patients. PLoS ONE, 2014, 9, e102764.	1.1	10
185	Analysis of signaling pathways in recurrent breast cancer. Genetics and Molecular Research, 2014, 13, 10097-10104.	0.3	6
186	SLUG: Critical regulator of epithelial cell identity in breast development and cancer. Cell Adhesion and Migration, 2014, 8, 578-587.	1.1	108
188	Molecular Markers for Breast Cancer: Prediction on Tumor Behavior. Disease Markers, 2014, 2014, 1-12.	0.6	126

#	ARTICLE	IF	CITATIONS
189	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. British Journal of Surgery, 2014, 101, 925-938.	0.1	34
190	Breast-Conserving Therapy for Triple-Negative Breast Cancer. JAMA Surgery, 2014, 149, 252.	2.2	67
191	Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. BMC Cancer, 2014, 14, 664.	1.1	43
192	Phosphoprotein Secretome of Tumor Cells as a Source of Candidates for Breast Cancer Biomarkers in Plasma. Molecular and Cellular Proteomics, 2014, 13, 1034-1049.	2.5	41
193	Molecular Biomarkers of Cancer Stem/Progenitor Cells Associated with Progression, Metastases, and Treatment Resistance of Aggressive Cancers. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 234-254.	1.1	74
194	Oestrogen receptors Î²1 and Î²cx have divergent roles in breast cancer survival and lymph node metastasis. British Journal of Cancer, 2014, 111, 918-926.	2.9	20
195	Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics Journal, 2014, 14, 93-106.	0.9	65
196	How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?. Journal of the National Cancer Institute, 2014, 106, dju165-dju165.	3.0	191
197	Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells. Molecular Cancer, 2015, 14, 72.	7.9	38
198	Triple-negative Breast Carcinoma. Advances in Anatomic Pathology, 2015, 22, 306-313.	2.4	13
199	A biologia do cÃ¢ncer de mama e testes moleculares de prognÃ³stico. Revista Hospital UniversitÃ¡rio Pedro Ernesto, 2015, 14, .	0.1	1
200	CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. PLoS ONE, 2015, 10, e0139112.	1.1	78
201	Reduced risk of breast cancer associated with recreational physical activity varies by HER 2 status. Cancer Medicine, 2015, 4, 1122-1135.	1.3	17
202	Decreased expression of SCUBE2 is associated with progression and prognosis in colorectal cancer. Oncology Reports, 2015, 33, 1956-1964.	1.2	18
203	Triple-Negative Breast Cancer. , 2015, , 463-472.		0
204	Alcohol and Breast Cancer: Reconciling Epidemiological and Molecular Data. Advances in Experimental Medicine and Biology, 2015, 815, 7-39.	0.8	18
205	CDKN2A (p14ARF/p16INK4a) and ATM promoter methylation in patients with impalpable breast lesions. Human Pathology, 2015, 46, 1540-1547.	1.1	23
206	Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. BMC Cancer, 2015, 15, 337.	1.1	16

#	Article	IF	Citations
207	Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study. BMC Cancer, 2015, 15, 460.	1.1	162
208	MELK kinase holds promise as a new radiosensitizing target and biomarker in triple-negative breast cancer. Journal of Thoracic Disease, 2016, 8, E1367-E1368.	0.6	6
209	Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study. Breast Cancer Research, 2016, 18, 62.	2.2	26
210	Serum N–glycan analysis in breast cancer patients – Relation to tumour biology and clinical outcome. Molecular Oncology, 2016, 10, 59-72.	2.1	34
211	PMCA2 silencing potentiates MDA-MB-231 breast cancer cell death initiated with the Bcl-2 inhibitor ABT-263. Biochemical and Biophysical Research Communications, 2016, 478, 1792-1797.	1.0	16
212	Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker. Oncology Reports, 2016, 36, 2489-2500.	1.2	32
213	Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma. Tumor Biology, 2016, 37, 13855-13870.	0.8	19
214	Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. International Journal of Cancer, 2016, 138, 2346-2356.	2.3	92
215	Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.. Acta Histochemica, 2016, 118, 176-182.	0.9	8
216	Selective Vulnerability of Cancer Cells by Inhibition of Ca2+ Transfer from Endoplasmic Reticulum to Mitochondria. Cell Reports, 2016, 14, 2313-2324.	2.9	195
217	Human breast cancer cell death induced by BnSP-6, a Lys-49 PLA2 homologue from Bothrops pauloensis venom. International Journal of Biological Macromolecules, 2016, 82, 671-677.	3.6	37
218	Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene, 2017, 36, 3553-3561.	2.6	11
219	Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Breast Cancer Research, 2017, 19, 10.	2.2	77
220	Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Research, 2017, 19, 6.	2.2	52
221	Deficiency of CCN5/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth. Scientific Reports, 2017, 7, 1220.	1.6	27
222	Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Scientific Reports, 2017, 7, 13856.	1.6	317
223	Immunosurveillance and Immunoediting of Breast Cancer via Class I MHC Receptors. Cancer Immunology Research, 2017, 5, 1016-1028.	1.6	20
224	Triple negative invasive lobular carcinoma of the breast presents as small bowel obstruction. International Journal of Surgery Case Reports, 2017, 37, 79-82.	0.2	2

#	Article	IF	Citations
225	Triple negative breast cancer: the kiss of death. Oncotarget, 2017, 8, 46652-46662.	0.8	129
226	Insensitivity to atorvastatin is associated with increased accumulation of intracellular lipid droplets and fatty acid metabolism in breast cancer cells. Scientific Reports, 2018, 8, 5462.	1.6	24
227	Association between mammographic density and tumor marker-defined breast cancer subtypes: a caseâ€"control study. European Journal of Cancer Prevention, 2018, 27, 239-247.	0.6	13
228	Protein expression profile and microRNA expression signature in estrogen receptor-positive and -negative breast cancers: report of two cases. Breast Cancer: Targets and Therapy, 2018, Volume 10, 195-199.	1.0	2
229	MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. Frontiers in Oncology, 2018, 8, 352.	1.3	13
230	Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis. Nature Communications, 2018, 9, 3486.	5.8	92
231	Triple-Negative Breast Cancer: A Comparison of Race and Survival. American Surgeon, 2018, 84, 881-888.	0.4	19
232	Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbeadâ€Assisted Flow Cytometry Detection of Tumorâ€Derived Extracellular Vesicles. Small Methods, 2018, 2, 1800122.	4.6	20
233	An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer. OncoTargets and Therapy, 2018, Volume 11, 4755-4768.	1.0	18
234	AR negative triple negative or â€œquadruple negativeâ€breast cancers in African American women have an enriched basal and immune signature. PLoS ONE, 2018, 13, e0196909.	1.1	47
235	Molecular Classification and Prognostic Signatures of Breast Tumors. , 2019, , 129-138.		0
236	Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 187.	3.5	16
237	In silico markers: an evolutionary and statistical approach to select informative genes of human breast cancer subtypes. Genes and Genomics, 2019, 41, 1371-1382.	0.5	3
239	High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Molecular Cancer Therapeutics, 2019, 18, 1696-1707.	1.9	24
240	Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancerâ€" A Comparison. Pathology and Oncology Research, 2020, 26, 833-844.	0.9	19
241	Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer. Clinical Breast Cancer, 2020, 20, 131-144.e3.	1.1	3
242	Viroimmunotherapy for breast cancer: promises, problems and future directions. Cancer Gene Therapy, 2021, 28, 757-768.	2.2	13
243	Identification of specific microRNAâ€"messenger RNA regulation pairs in four subtypes of breast cancer. IET Systems Biology, 2020, 14, 120-126.	0.8	2

#	ARTICLE	IF	CITATIONS
244	DEAD-box RNA Helicase 39 Promotes Invasiveness and Chemoresistance of ER-positive Breast Cancer. Journal of Cancer, 2020, 11, 1846-1858.	1.2	5
245	NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells. Cancer Treatment and Research Communications, 2021, 27, 100340.	0.7	2
246	Bardet-Biedl Syndrome 4 in Early Diagnosis and Prognosis of Breast Cancer. , 0, 83, .		1
247	Overview of recent advances in metastatic triple negative breast cancer. World Journal of Clinical Oncology, 2021, 12, 164-182.	0.9	42
248	Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence. Histopathology, 2021, 79, 139-159.	1.6	9
249	Revealing nuclear receptor hub modules from Basal-like breast cancer expression networks. PLoS ONE, 2021, 16, e0252901.	1.1	0
250	The Value of EphB2 Receptor and Cognate Ephrin Ligands in Prognostic and Predictive Assessments of Human Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 8098.	1.8	8
251	Functional multigenic variations associated with hodgkin lymphoma. International Journal of Laboratory Hematology, 2021, 43, 1472-1482.	0.7	5
252	A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer. Cancer Biology and Therapy, 2021, 22, 1-13.	1.5	2
253	Molecular Oncology of Breast Cancer. , 2009, , 501-531.		1
254	Immunohistochemical profile and clinical-pathological variables in breast cancer. Revista Da Associação Médica Brasileira, 2012, 58, 178-187.	0.3	6
256	Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the "Basal" Breast Cancer Subgroup. PLoS ONE, 2009, 4, e4710.	1.1	88
257	miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors. PLoS ONE, 2011, 6, e16915.	1.1	278
258	Identifying In-Trans Process Associated Genes in Breast Cancer by Integrated Analysis of Copy Number and Expression Data. PLoS ONE, 2013, 8, e53014.	1.1	54
259	Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model. PLoS ONE, 2013, 8, e58183.	1.1	35
260	Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. PLoS ONE, 2013, 8, e75038.	1.1	114
261	Alu and LINE-1 Hypomethylation Is Associated with HER2 Enriched Subtype of Breast Cancer. PLoS ONE, 2014, 9, e100429.	1.1	66
262	Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach. PLoS ONE, 2015, 10, e0129610.	1.1	5

#	ARTICLE	IF	CITATIONS
263	*CHL1* hypermethylation as a potential biomarker of poor prognosis in breast cancer. Oncotarget, 2017, 8, 15789-15801.	0.8	32
264	Mitochondrial calcium uniporter as a target of microRNA-340 and promoter of metastasis via enhancing the Warburg effect. Oncotarget, 2017, 8, 83831-83844.	0.8	55
265	Transcriptional signature of lymphoblastoid cell lines of *BRCA1*, *BRCA2* and non-*BRCA1/2* high risk breast cancer families. Oncotarget, 2017, 8, 78691-78712.	0.8	8
266	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	0.8	58
267	BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. Current Drug Targets, 2020, 21, 962-973.	1.0	8
268	miR-205 in Breast Cancer: State of the Art. International Journal of Molecular Sciences, 2021, 22, 27.	1.8	33
269	Case Series of Different Onset of Skin Metastasis According to the Breast Cancer Subtypes. Cancer Research and Treatment, 2014, 46, 194-199.	1.3	9
270	Spontaneous Mammary Carcinomas in Female Dogs: Association between Immunohistochemical Degrees of Neoplasia Aggressiveness and Residual Pyrethroids. Open Journal of Veterinary Medicine, 2012, 02, 207-215.	0.4	1
271	Le phénotype biologique du potentiel métastatique des cancers du sein existe-t-il ?. , 2007, , 27-46.		0
273	Critical Roles of Tumorigenic and Migrating Cancer Stem/Progenitor Cells in Cancer Progression and their Therapeutic Implications. , 2009, , 287-308.		0
274	New Perspectives for Therapy Choice. Cancer Treatment and Research, 2009, 151, 31-40.	0.2	0
275	Targeted Therapy for Breast Cancer: A Focus on HER2/neu and Antiangiogenic Therapy. , 2009, , 513-521.		0
276	Investigational Molecular Prognostic Factors for Breast Carcinoma. , 2009, , 463-475.		0
277	Introduction on Genome-wide Expression Profiling from Formalin-Fixed Paraffin-Embedded Tissues Using Microarrays. , 2011, , 233-237.		0
278	Invasive Ductal Carcinoma of No Special Type and Histologic Grade. , 2012, , 429-445.		1
279	Each patients cancer is like fingerprint: where are we in molecular profiling in breast cancer diagnosis?. Medical Science and Discovery, 2014, 1, 2.	0.1	0
280	Molecular Medicine and Personalized Therapy for Breast Cancer Patients. , 2015, , 321-334.		0
281	Immunohistochemical profile and its association with clinicopathological parameters in carcinoma breast: a prospective study in central India. International Journal of Research in Medical Sciences, 2019, 7, 1796.	0.0	1

#	Article	IF	Citations
283	Computational disease progression modeling can provide insights into cancer evolution. Oncoscience, 2020, 7, 21-22.	0.9	1
284	Evaluation of early post-natal pig mammary gland development and human breast cancer gene expression. Developmental Biology, 2022, 481, 95-103.	0.9	4
285	Classification moléculaire des cancers du sein. Implications pratiques. , 2007, , 289-295.		0
286	Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns. Cancer Informatics, 2007, 2, 243-74.	0.9	9
287	Establishing a population-based cancer registry DNA biorepository: the Hawai'i Tumor Registry's Sharing Ohana project. Hawaii Medical Journal, 2009, 68, 171.	0.4	0
288	New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histology and Histopathology, 2010, 25, 1057-73.	0.5	37
289	The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China. Oncologist, 2022, 27, e1-e8.	1.9	5
290	RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance. Diagnostic Pathology, 2022, 17, 1.	0.9	15
291	SENP1 promotes triple-negative breast cancer invasion and metastasis via enhancing CSN5 transcription mediated by GATA1 deSUMOylation. International Journal of Biological Sciences, 2022, 18, 2186-2201.	2.6	9
294	A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes. Npj Breast Cancer, 2022, 8, .	2.3	30
295	Fate decisions of breast cancer stem cells in cancer progression. Frontiers in Oncology, 0, 12, .	1.3	1
296	Triple-Negative Breast Cancer (TNBC): Clinical Features and Therapeutic Targets. , 2022, , 1-14.		0
297	The distinguishing electrical properties of cancer cells. Physics of Life Reviews, 2022, 43, 139-188.	1.5	9
298	Learning to distinguish progressive and non-progressive ductal carcinoma in situ. Nature Reviews Cancer, 2022, 22, 663-678.	12.8	8
299	Crosstalk between Depression and Breast Cancer via Hepatic Epoxide Metabolism: A Central Comorbidity Mechanism. Molecules, 2022, 27, 7269.	1.7	1
300	Breast cancer: age incidence, hormone receptor status and family history in Najaf, Iraq. Journal of Medicine and Life, 2022, 15, 1318-1321.	0.4	0
301	Evaluation of forkhead-box C1 expression in breast cancer: Prognostic value and histopathological correlations in Egyptian women. Egyptian Journal of Pathology, 2022, 42, 62.	0.0	0
302	Triple-Negative Breast Cancer (TNBC): Clinical Features and Therapeutic Targets. , 2023, , 819-832.		0

#	ARTICLE	IF	CITATIONS
303	A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620). Breast Cancer Research and Treatment, 2023, 198, 487-498.	1.1	0
304	Clinical significance of Notch receptors in triple negative breast cancer. Breast Disease, 2023, 42, 85-100.	0.4	0